Tissue Lipidomic Alterations Induced by Prolonged Dexamethasone Treatment

Abstract

Dexamethasone is a synthetic glucocorticoid medication vastly used to treat abnormal immune responses and inflammation. Although the medication is well-established in the medical community, the prolonged treatment with high dosages of dexamethasone may lead to severe adverse effects through mechanisms that are not yet well-known. Lipids are a large class of hydrophobic molecules involved in energy storage, signaling, modulation of gene expression, and membranes. Hence, untargeted lipidomics may help unravel the biochemical alterations following prolonged treatment with high dosages of dexamethasone. We performed comprehensive lipidomic analyses of brain, heart, kidney, liver, and muscle samples obtained from rats that were treated with intramuscular injections of dexamethasone for 14 weeks compared to healthy controls. The employed methodology and statistical analysis showed that phosphatidic acids, glycerophospholipids, plasmalogens, and fatty acids are deeply affected by prolonged use of the medication. Brain tissue was only mildly affected, but skeletal muscle showed a strong accumulation of lipids that may be correlated with alterations in the energy metabolism, myopathy, and oxidative processes. This work provides new insights into the mechanisms of action and adverse effects for one of the most commonly prescribed class of drugs in the world.

Emodin ameliorates acute pancreatitis‑induced lung injury by suppressing NLRP3 inflammasome‑mediated neutrophil recruitment

“…Its use for therapeutic intervention has been reported in SAP-associated ALI (44). However, DEX treatment gives rise to some adverse effects in patients, including fungal infection, hyperglycemia, sleep insomnia and rapid weight gain (45).…”

Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson’s Disease

“…Lipids can have a high number of isomers and isobars that may belong to different subclasses. Hence, we employed a 6-tier filtering and scoring approach based on the expected behavior for each lipid subclass to select the best mass-match identification. − All identification possibilities for each detected feature that passed initial exclusion filters for an expected retention time and adduct form were ranked according to the characteristics of the corresponding lipid subclass. The top choice for each feature was selected by the total score and used to determine lipid class for normalization, but other identification possibilities that passed the initial exclusion filters for retention time range and adducts were also kept, ordered by total score values, as they may represent isomeric or isobaric overlaps that could not be resolved without targeted methodologies.…”

“…Our laboratory is involved in developing techniques for both metabolome and lipidome analyses to achieve as high coverage as possible. For metabolomics, we have developed a high-performance chemical isotope labeling (CIL) liquid chromatography mass spectrometry (LC–MS) platform for comprehensive and quantitative metabolome analysis. ,− Recently, we have also reported our studies of isotope-standard-assisted high-resolution LC–MS for untargeted lipidome analysis of biological samples. ,− These technical developments offer a unique opportunity to investigate the metabolome and lipidome for biological studies and disease biomarker discovery. The study of different omics technologies has great potential for improving early prognosis and elucidating biochemical pathways involved in the pathogenesis and progression of human diseases .…”

Potent Anti-Inflammatory, Arylpyrazole-Based Glucocorticoid Receptor Agonists That Do Not Impair Insulin Secretion

“…GCs are a staple of modern medicine due to their anti-inflammatory and immunomodulatory effects. GC-based therapies have been successfully applied to treating a wide range of inflammatory conditions, autoimmune disorders, and cancersin addition to aiding in organ and tissue transplantation. − Despite the obvious beneficial properties of GCs, they pose a long list of serious side effects including Cushing’s disease, muscle atrophy, metabolic syndrome, osteoporosis, and diabetes. − In recent years, reducing autoimmune-mediated inflammation in patients at risk for developing steroid induced diabetes mellitus (SIDM) has been of interest; however, current GC therapies are known to be diabetogenic by transcription-mediated mechanisms that modify the secretion of insulin from pancreatic β-cells, regulate β-cell proliferation, alter body composition, and promote insulin resistance. − The reduction in insulin sensitivity places extra stress on β-cells to produce increasing quantities of insulin, which increases the risk of β-cell failure. , The need for improved GC agonist compounds is due to side effects of current compounds upon chronic use, such as immunosuppressive agents for organ transplants. This long-term usage dramatically increases the risk for diabetes. , …”